{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T09:45:46Z","timestamp":1700041546797},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2005,10,21]],"date-time":"2005-10-21T00:00:00Z","timestamp":1129852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1038\/sj.eye.6702115","type":"journal-article","created":{"date-parts":[[2005,10,21]],"date-time":"2005-10-21T16:26:39Z","timestamp":1129911999000},"page":"1082-1083","source":"Crossref","is-referenced-by-count":1,"title":["The natural history of Vigabatrin-associated visual field defects in patients electing to continue their medication"],"prefix":"10.1038","volume":"20","author":[{"given":"N","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Jivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,10,21]]},"reference":[{"issue":"1","key":"BF6702115_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.eye.6701405","volume":"19","author":"JL Best","year":"2005","unstructured":"Best JL, Acheson JF . The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication. Eye 2005; 19 (1): 41\u201344.","journal-title":"Eye"},{"key":"BF6702115_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","volume":"314","author":"T Eke","year":"1997","unstructured":"Eke T, Talbot JF, Lawden MC . Severe persistent visual field constriction associated with Vigabatrin. BMJ 1997; 314: 180\u2013181.","journal-title":"BMJ"},{"key":"BF6702115_CR3","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/bmj.317.7168.1322","volume":"317","author":"RE Appleton","year":"1998","unstructured":"Appleton RE . Guideline for prescribing Vigabatrin. BMJ 1998; 317: 1322.","journal-title":"BMJ"},{"issue":"7246","key":"BF6702115_CR4","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1136\/bmj.320.7246.1404","volume":"320","author":"Vigabatrin Paediatric Advisory Grou","year":"2000","unstructured":"Vigabatrin Paediatric Advisory Group. Guideline for prescribing Vigabatrin in children has been revised. BMJ 2000; 320: 1404\u20131405.","journal-title":"BMJ"},{"key":"BF6702115_CR5","unstructured":"http:\/\/www.rcophth.ac.uk\/members\/members-documents\/Vigabatrin.pdf\n                    \n                  ."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6702115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6702115","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6702115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:22:52Z","timestamp":1684412572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6702115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,21]]},"references-count":5,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["BF6702115"],"URL":"https:\/\/doi.org\/10.1038\/sj.eye.6702115","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,21]]}}}